Reflecting on 2024: A Year-End Message from Craig Cooper, Cardiex CEO 

As 2024 comes to a close, I want to take a moment to reflect on the extraordinary progress we’ve made this year at Cardiex. It’s been a year of transformation, innovation, and growth—one that I am genuinely proud to share with you. 

This year, we’ve reaffirmed our commitment to advancing cardiovascular health through groundbreaking technologies, impactful partnerships, and tireless research. Building on the trends we forecasted at the beginning of the year—personalization, accessibility, and data-driven insights—we have seen these predictions come to life through our work. From launching innovative products to earning global recognition for maternal health research, 2024 has been about pushing boundaries and shaping the future of vascular health. 

Early Momentum in Research and Recognition

We kicked off the year with the launch of the inaugural Cardiex Arterial Research Initiative (CARI). Designed to propel research in arterial stiffness and vascular health, this initiative, supported by a $100,000 prize pool, brought together researchers from across the globe with a shared passion for advancing cardiovascular care. By June, we celebrated some truly exceptional projects, including our grand prize winner, Zemin Kuang of Beijing Anzhen Hospital. The creativity and insights from the runners-up and Voter Spotlight Honorees set the tone for an inspiring year of collaboration and discovery. 

Another early highlight was the inclusion of the CONNEQT Pulse on the US Blood Pressure Validated Device List (VDL), a major milestone that underscores the reliability and accuracy of our technology. These early successes energized us for the months ahead. 

Mid-Year Growth: Expanding Expertise and Influencing the Field

In Q2, we welcomed two exceptional leaders to our team. Dr. Sanjeev Bhavnani joined us as Chief Clinical Officer, bringing decades of expertise in digital health and clinical innovation, while Brian Schaechter rejoined us as Senior Director of Sales – Pharmaceutical, enhancing our ability to support clinical trial solutions. Their leadership has enriched our research capabilities and client partnerships. 

In May, our commitment to advancing vascular health insights took center stage during a fireside chat with the American Heart Association (AHA) This engaging discussion, moderated by our Chief Strategy Officer Catherine Liao, explored the intricacies of vascular aging, preventive strategies, and the evolving role of digital biomarkers in shaping cardiovascular care. 

These achievements reflect the growing impact of multi-modal data integration, a key trend we identified for 2024. By combining insights from pulse wave analysis, heart rhythm, and arterial stiffness, our tools empower clinicians to address complex cardiovascular challenges with greater precision. 
 
Throughout the quarter, our team also traveled extensively to foster relationships and showcase our technology’s impact at key industry events, including the American College of Sports Medicine (ACSM) Annual Meeting, North American Artery (NAA) Conference, and the Drug Information Association (DIA) Global Annual Meeting. It’s always inspiring to connect with our partners and see firsthand how our solutions are transforming the field. 

Breaking New Ground in Research and Applications

In Q3, we marked the publication of a peer-reviewed study validating our wearable fingertip photoplethysmography (PPG) technology for non-invasive cardiovascular monitoring. Published in the journal Pulse, this research demonstrated the device’s ability to capture over 20 clinically relevant cardiovascular parameters, including central systolic and diastolic blood pressure. These findings are a testament to the growing adoption of continuous monitoring technologies and the shift towards personalized, data-driven care. 

We also deepened our investment in maternal health research. At ARTERY 2024, Cardiex Research Associate Gisele Bentley presented her meta-analysis on the role of aortic biomarkers in predicting preeclampsia development. By offering non-invasive methods to assess maternal cardiovascular risks, this research highlights the transformative potential of digital vascular biomarkers in safeguarding maternal and fetal health. 

Closing the Year with Momentum

As the year drew to a close, we highlighted a major achievement: winning the $525,000 grand prize in the RADx Tech for Maternal Health Challenge, recognizing our work in leveraging non-invasive cardiovascular monitoring technologies to address maternal health disparities. This honor capped a two-year journey that brought nearly $1 million in total funding and positioned Cardiex as a leader in advancing maternal care. 

Another milestone was the CONNEQT Pulse moving into production, with pre-sales opening to a waitlist of over 22,000 individuals. We are thrilled to begin shipping early next year, with solutions that improve clinical trial efficiency through seamless at-home biomarker collection, real-time reporting, and patient monitoring via the Pulse App and Clinical Trial Physician Portal, improving both accessibility and data integration for decentralized trials. 

Our global presence remained strong as we showcased our technologies at key events such as MEDICA, Pulse of Asia, Hypertension Australia, and A4M LongevityFest. These gatherings emphasized our commitment to collaboration and our vision of making cardiovascular health insights accessible to clinicians, researchers, and patients worldwide. 

At the recent A4M, we announced a new CONNEQT partnership with Joseph M. Raffaele, MD and his PhysioAge practice to redefine how cardiovascular aging is measured and managed. Beginning in January 2025, this partnership will expand access to advanced vascular aging insights for PhysioAge Analytics subscribers. 

Looking Ahead

As I look back on 2024, I am incredibly proud of what we’ve accomplished together. The trends we predicted—personalization, accessibility, and data-driven care—have shaped everything we’ve done this year and will continue to drive us forward in 2025. 

But our work is far from over. With the support of our partners, collaborators, and team, we will continue to push the boundaries of innovation to improve cardiovascular health, extend health spans, and transform lives. 

Thank you for being a part of this journey. I’m excited for what’s ahead and look forward to sharing even more progress with you in the coming year. Let’s make 2025 a year of even greater impact—together. 

Craig Cooper
CEO, Cardiex